Yes – in certain U.S. states you can sell R&D tax credits to other companies, turning unused tax breaks into cash. Shockingly, an estimated $60 billion in R&D tax credits went unclaimed in 2019, showing how much funding gets left on the table. In this guide, you’ll discover:
- 🗺️ Where and who can actually sell R&D credits – the federal rules vs. state programs (NJ, PA, AZ, etc.) and which tech startups qualify.
- 🔄 How the process works – from IRS Form 6765 and state applications to credit transfer certificates, buyers, and the one-time transfer rules.
- 💰 Why it’s done – the big benefits for startups (non-dilutive cash infusion) and for buyers, plus why states allow these transfers to spur innovation.
- ⚖️ Pros and cons – immediate funding vs. discounts and limitations, and a 2-column table comparing the advantages and drawbacks of selling your credits.
- 🚩 Common pitfalls to avoid – eligibility missteps, missing deadlines, undervaluing credits, compliance risks, and other mistakes when monetizing R&D tax incentives.
R&D Tax Credits 101: Federal vs. State Context
What are R&D tax credits? The Research & Development tax credit (under IRC §41) is a government incentive rewarding companies for investing in innovation. It’s a dollar-for-dollar credit that reduces your tax bill for qualifying research expenses (QREs like engineers’ wages, lab supplies, prototypes, etc.). At the federal level, the R&D credit has been permanent since 2015 and is claimed on IRS Form 6765. Nearly 40 U.S. states also offer their own R&D credits, following similar rules for qualified research but with state-specific twists.
Federal R&D credit – valuable but non-transferable. Under federal tax law, you generally cannot sell or transfer your R&D credits to another taxpayer. The credit is tied to the company that earned it – it can offset that company’s federal income tax or be carried forward up to 20 years, but it cannot be sold like a commodity. In other words, the IRS won’t let one business buy another’s R&D credits to reduce their own taxes. This non-transferability ensures the benefit rewards the company doing the R&D. However, this creates a problem for startups and small businesses that have little or no taxable profit – they often accumulate credits they can’t currently use. Those unused credits just sit carried-forward, providing zero immediate benefit to cash-strapped innovators.
Federal workaround for startups. Congress recognized this issue and added a special “startup provision” in the Protecting Americans from Tax Hikes (PATH) Act of 2015 (expanded further by the 2022 Inflation Reduction Act). Now, qualifying new businesses can’t sell their federal credits, but they can apply up to $500,000 per year of R&D credits against payroll taxes instead of income tax. This essentially monetizes the credit for startups with no income – they get a break on Social Security payroll taxes (up to $500k, doubled from $250k as of 2023) which effectively puts cash back in their pocket. It’s not “selling” to another company, but it’s a federal way to unlock credit value early for companies under ~5 years old with under $5 million gross receipts. Aside from this payroll offset, the U.S. government doesn’t offer direct refunds or sales of the federal R&D credit – you either use it to reduce your own tax or carry it forward.
State R&D credits – a different story. Many state governments have taken a more flexible approach to ensure companies see value from their credits. While some states simply mirror federal rules (non-refundable, carryforward only), others allow alternative monetization: either refundable credits (the state pays you cash for the credit) or transferable credits (you sell the credit to another taxpayer). In fact, about nine states offer refundability for R&D credits, and a handful explicitly allow selling or transferring R&D credits to another company. States implement these policies to attract tech investment – if a startup knows it can trade its credits for cash, it’s more likely to conduct R&D and create jobs in that state. This set the stage for a secondary market for state tax credits, where buyers (usually profitable companies owing taxes) and sellers (often loss-making startups) exchange credits under state oversight.
So, can you “sell” an R&D tax credit? At the federal level, no – you cannot sell your IRS R&D credits to anyone (the law provides only the payroll tax offset as an alternative). At the state level, yes – if you are in one of the states that explicitly permit R&D credit transfers or sales. Below, we’ll dive into where and how this works, and the specific programs in place to facilitate these sales.
Where Can R&D Tax Credits Be Sold? (State-by-State)
Only a limited number of U.S. states allow businesses to sell or transfer their R&D tax credits. Each state has its own rules about who qualifies to sell credits, how much can be sold, and how the sale is executed. Let’s break down the major state programs that turn R&D credits into a cash opportunity:
New Jersey’s Tech Lifeline: Sell Credits via the NOL Program
New Jersey is famous for its pioneering R&D credit transfer initiative. The New Jersey Technology Business Tax Certificate Transfer Program – often called the NOL Program – lets approved tech and biotech startups sell their unused New Jersey net operating losses (NOLs) and R&D tax credits to other NJ companies. In essence, an eligible startup gets a check for its tax credits, and a profitable corporation buys those credits to slash its NJ tax bill. This program has been a lifesaver for many Garden State startups: since its inception in 1999, over 580 companies have raised nearly $2 billion in funding by selling tax losses and R&D credits.
How it works: Each year, NJ allocates a pool (currently $75 million annually) for these transfers. A startup applies to the NJ Economic Development Authority (NJEDA) by the deadline (usually June 30) to sell its credits/NOLs. If approved, the company can sell up to $15 million total (lifetime) of tax benefits. Crucially, New Jersey requires that the sale price be at least 80% of the credit’s value – meaning the startup gets at least $0.80 on the dollar. (In practice, many deals are at that 80% minimum.) For example, if a biotech has $1 million in NJ R&D credits it can’t use, an established NJ corporation might buy them for $800,000 cash. The buyer then uses the $1M credit to reduce its own NJ corporate tax (and cannot resell it). Both sides win: the startup gets non-dilutive cash to fund R&D, and the buyer saves $200k (paying $800k for a $1M tax reduction). The state wins too – it keeps the startup’s R&D activity in NJ and still ultimately forgoes only the same $1M in tax revenue, just to a different taxpayer.
Who qualifies: New Jersey sets strict eligibility to ensure the program targets genuine early-stage innovators. To sell R&D credits (or NOLs) a company must: be an incorporated NJ tech or biotechnology business, have < 225 employees (with >50% of them in NJ), own proprietary IP (patents or patents-pending, etc.), and have no positive net income in the last two years (i.e. be genuinely unprofitable). You also need to offer health benefits to employees and commit to spend the sale proceeds on growth and R&D in New Jersey. If a company relocates out of NJ or misuses the funds, it could be required to repay the assistance. These safeguards keep the program’s integrity (no selling credits just to pocket cash without investing in NJ’s economy).
Process: Once approved by NJEDA, the startup is issued a tax credit transfer certificate for the amount of credits/NOLs it can sell. The company typically lines up a buyer (sometimes on its own or via brokers/NJEDA’s network) – often large NJ corporations looking to reduce tax. The sale is executed (with NJEDA’s sign-off), and the buyer then claims the credit on its NJ tax return using that certificate. The credit can only be used in the year of purchase (no long carryforwards for the buyer), and it can’t be sold again. For the startup, the cash received is generally treated as non-dilutive financing – it doesn’t count as taxable income under NJ law (it’s effectively like a state grant), though for federal tax purposes it may need careful treatment. The end result: New Jersey’s program turns otherwise dead credits into vital capital for startups. Governor Phil Murphy and NJEDA have touted this as a way to foster innovation – and indeed, year after year, dozens of NJ startups (34 companies in the 2023 round) sell their tax credits to raise collectively tens of millions in cash.
Pennsylvania’s R&D Credit Exchange: Assignment Program
Pennsylvania also allows companies to sell their state R&D credits, through what’s known as the R&D Tax Credit Assignment Program. Pennsylvania’s approach is slightly different but shares the goal of getting value into the hands of R&D performers who can’t use the credits themselves. Each year PA awards up to $55 million in R&D credits (with $11M earmarked for small businesses). Companies conducting qualified R&D in Pennsylvania apply to the state (Dept. of Revenue) by September 15 for credit on their R&D expenses from the prior year. Once the state awards these credits (usually by December), the company can use the credit to offset PA taxes or apply to sell (“assign”) the unused credit to another taxpayer.
How it works: A business with an awarded PA R&D credit that it won’t fully use can seek approval from the PA Department of Community & Economic Development (DCED) to assign (sell) the credit to another entity. Unlike NJ, Pennsylvania does not mandate a minimum 80% price – in practice, market forces set the price (often around 90¢ on the dollar for PA credits, depending on buyer demand). There are some key conditions: the credit can only be sold once (no chain of resales), and the seller must apply its credit to its own tax liability first for that year, using only the excess for sale. In other words, if you owe any PA tax, you must use your credit to pay that before selling the remainder. This ensures companies don’t sell credits they actually needed to pay their own tax.
Buyer usage rules: The buyer of a PA R&D credit must use it in the tax year of purchase. Additionally, a purchaser can only use bought credits to offset up to 75% of its tax liability for that year (this prevents a company from zeroing out its tax entirely via purchased credits). Any credit a buyer can’t use (due to the 75% limit or if they bought more than their tax bill) is basically lost – PA does not allow the buyer to carry forward a purchased credit or get a refund. So buyers will typically only purchase what they know they can use. The buyer also cannot resell the credit to anyone else.
Who qualifies to sell: Pennsylvania’s eligibility is broad – any company or individual that earns a PA R&D credit can sell it, as long as they are tax-compliant (all state filings up to date, no delinquent taxes owed) and they follow the application process. PA historically had a sunset on the credit program, but that was repealed in 2016, making the R&D credit (and assignment ability) permanent. Small businesses (defined in PA as having net assets < $5M) particularly benefit since $11M of the annual credits are reserved for them and they often can’t use the credits fully. Pennsylvania’s program, in effect, lets a startup monetize a state R&D credit that would otherwise carry forward 15 years or expire – instead of waiting, they get cash now to reinvest. For example, a Philly-based tech company that earned a $100k PA R&D credit and owes no PA taxes could sell it to a profitable PA manufacturer for perhaps $85k–$90k in cash. The startup gets funding for payroll and research, while the manufacturer saves on its taxes (within the 75% usage cap).
Process: The selling company notifies DCED of the planned credit assignment and submits a transfer application (often along with the buyer’s details and the agreed price). The state reviews it, ensures both parties are eligible (and that the credit amount is correct and not needed by seller to cover its own taxes), then approves the transfer. The state issues a certificate or letter to the buyer confirming the credit amount they can claim. Come tax time, the buyer attaches that to their PA tax return to get the credit. Meanwhile, the seller receives the agreed payment from the buyer (usually facilitated by a broker or directly if the parties connected). Pennsylvania does not charge a big fee for this, though professional brokers might take a small commission for matching buyers and sellers. Overall, PA’s system has been actively used – between 2003 and 2017 the state authorized over $600 million in R&D credits, a portion of which changed hands through assignments, fueling the growth of many local startups.
Arizona: Refundable Credits (Cash for 75% Value)
Arizona takes a slightly different route to help companies monetize R&D credits: rather than a sale to another taxpayer, Arizona offers a partial refund option. Essentially, small R&D-focused businesses in AZ can choose to “sell” their credit back to the state in exchange for 75% of its value in cash. This is like the state buying your credit at a discount. While not a private sale, it achieves a similar result – the company gets immediate cash for a credit it can’t use, and the state forgoes a portion of the credit (keeping 25% as savings).
How it works: Arizona’s R&D tax credit can be sizable (24% of the first $2.5M of qualifying R&D expenditures, 15% on amounts above that). It’s normally nonrefundable (can carry forward 10–15 years). But if you are a “Small Business” (defined as having <150 full-time employees), Arizona lets you apply for a Refundable R&D Credit. You must get pre-approval from the Arizona Commerce Authority (ACA) and a Certificate of Qualification. If granted, you can elect to receive 75% of your credit as a refund from the state. The remaining 25% of the credit is forfeited. For example, if a qualifying startup earned a $100,000 Arizona R&D credit and has no AZ tax due, it can opt to get a $75,000 check from the state (and the other $25k of credit is unused). This effectively monetizes the credit without needing a private buyer.
Limits: Arizona caps the total refundable credits at $5 million per year statewide (first-come, first-served). Companies have to apply early and once the cap is met, others have to carry forward their credits instead. The refundable option also doesn’t apply to any extra boost credit for university research collaborations – that portion you can only carry forward. Notably, Arizona is listed among “transferable” credit states in some reports because this refund is akin to a transfer (though it’s really a state-run buyback). Arizona does not allow selling the credit to another private company; the mechanism is between the business and the state.
Why it helps: For Arizona startups and small tech firms, this is a great way to get cash now rather than wait years to use a credit. It’s especially useful for companies that are pre-revenue or reinvesting everything in growth. Many early-stage businesses in Arizona use the 75% refund to fund new research projects or hiring, essentially plowing the money right back into innovation (which is exactly what the state wants to encourage).
North Dakota: Transfer for New Companies
North Dakota is another state that permits R&D credit sales, but in a very narrow scenario. A provision in ND law allows a “qualified research company” to sell up to $100,000 of unused North Dakota R&D credits if the company is a small new business. Specifically, the company must have started conducting R&D in ND after 2016 and have less than $750,000 in annual gross revenue. If those conditions are met, the business can transfer (sell) up to $100k of its ND research credits to another ND taxpayer. This is designed as a way for brand-new tech startups to get some immediate funding from their credits.
Practical impact: The $100k limit means this isn’t a windfall, but for a tiny startup, selling $100k of credits might yield roughly $80k in cash (assuming a buyer pays ~80% value) – enough to perhaps hire another engineer or buy equipment. North Dakota likely included this to boost its entrepreneurial ecosystem by turning tax credits into seed capital. The rules ensure only genuinely small, emerging companies (under $750k revenue) can do it, preventing larger firms from gaming the system. The state benefits by seeding those companies and hopefully seeing them grow (and pay taxes later).
Process: The company would apply to the ND Office of State Tax Commissioner for approval to transfer credits, and they must find a willing buyer (often a local profitable business). The buyer uses the purchased credit to cut their ND income tax. ND also allows R&D credits to be carried back 3 years or forward 15, so selling is just one option if immediate cash is needed. Because of the tight eligibility, this provision isn’t as widely utilized as NJ’s or PA’s programs, but it’s an important lifeline for the few companies that qualify each year in North Dakota’s growing tech sectors (e.g. agri-tech startups or software firms in Fargo).
Other States & Approaches
Beyond NJ, PA, AZ, and ND, a few other states have quirks to note:
- Connecticut – Small businesses with under $70 million in gross income and no tax liability can exchange unused Connecticut R&D credits for a 65% refundable credit from the state. This is similar to Arizona’s idea: CT basically buys the credit for 65 cents on the dollar. It’s not a sale to another taxpayer, but it’s a way to get cash for your credits (particularly helpful for Connecticut’s many biotech firms).
- Arkansas – While generally nonrefundable, Arkansas allows certain targeted R&D projects (approved by their economic development authority) to sell their credits upon state approval. This is meant for strategic high-impact research ventures in Arkansas; a company can do an R&D project under a special program and if eligible, get a credit and sell it to another Arkansas taxpayer.
- Kansas – Starting in 2023, Kansas enacted a new rule allowing businesses with no current tax liability to transfer their R&D credit one time to another taxpayer. Both parties must file forms with the state (K-53 for credit and K-260 for transfer). Kansas previously had unused credits just carry forward, but now a company can effectively monetize it by transferring to someone who can use it that year. This new transferability reflects a trend of more states recognizing the value of making credits liquid.
- Massachusetts, New York, etc. – Some large states like CA, NY, MA explicitly do not allow selling R&D credits (and their credits are nonrefundable). However, they offer long carryforwards (Massachusetts, for example, lets you carry R&D credits forward indefinitely) so eventually a profitable company can use them. But for a startup, that’s cold comfort – hence many Massachusetts and California startups push for federal payroll credit or locate activities in states like CT or NJ that offer better monetization.
In summary, only a handful of states permit true transfer of R&D credits to another taxpayer (notably New Jersey, Pennsylvania, Arizona, and a few others in special cases). Several more allow refunds or exchanges (effectively selling back to the state). Most states simply provide non-transferable credits that must be used by the company or carried over. If you’re operating in multiple states, it’s crucial to know the specific incentive landscape: a “transferable” R&D credit in one state can be a significant funding source, whereas in another state your credit might be locked up until you have profits.
Quick Reference – Popular R&D Credit Transfer Scenarios:
To recap the most common scenarios where R&D credits get sold, here’s a snapshot of how it plays out in top states:
| State & Program | How Credits Are Sold (Scenario) |
|---|---|
| New Jersey (Technology NOL Transfer) | Unprofitable NJ tech/biotech startups sell unused R&D credits (and NOLs) to profitable NJ companies for at least 80% of value. State-run program (annual cap $75M) facilitates issuing transfer certificates. |
| Pennsylvania (R&D Credit Assignment) | Companies with PA R&D credits can assign/sell unused credits to other PA taxpayers after state approval. Credits sell at market rates (~85–90%), one-time transfer, buyer must use in purchase year (max 75% of tax liability). |
| Arizona (Refundable Credit Option) | Eligible small businesses (<150 employees) “sell” credits back to state for 75% cash refund. No private buyer needed – state issues refund for 75% of credit’s value (annual state payout cap $5M). |
| North Dakota (Limited Transfer) | New small R&D companies (<$750k revenue) in ND can transfer up to $100k of credits to another taxpayer. Provides quick cash (around 80% of $100k) for startups; buyer uses credit on ND taxes that year. |
As shown, New Jersey and Pennsylvania have robust marketplaces for credits between companies, Arizona and Connecticut effectively let you cash in via the government, and states like North Dakota or Arkansas allow limited cases. Now that we know where credits can be sold and the basic mechanics, let’s explore how to actually execute a sale, and the why behind these transactions.
How Do You Sell an R&D Tax Credit? (Process Overview)
Selling an R&D credit isn’t as simple as posting it on eBay – it’s a regulated process involving state approvals and paperwork. Here’s a general step-by-step of how an R&D credit sale or transfer works in states that allow it:
- Earn and claim the credit: First, your company must actually generate an R&D tax credit by performing qualified research and filing the necessary state credit application or form. Often this means completing your state’s R&D credit form (many states piggyback on Form 6765 calculations) and applying by a deadline. For example, you apply to NJEDA or to PA’s Revenue department to receive the credit allocation. This establishes the amount of credit you have available to use or sell.
- Meet eligibility and get approval: Ensure you qualify under any state-specific eligibility rules before attempting to sell. (Each program – NJ, PA, etc. – has criteria on company size, industry, etc., as we covered.) You typically need to apply for permission to transfer the credit. This could be a transfer application to a state agency (like PA’s DCED or ND’s Tax Commissioner). The state will review your request – confirming you have the credit available, you’re in good standing on taxes, and you meet all requirements (e.g. NJ checks employee count, IP ownership, etc.). Once approved, the state issues some form of certificate or approval letter for the transfer.
- Find a buyer and agree on price: In parallel with approval, you usually must line up a buyer who is willing to purchase your credit. Buyers are generally profitable companies (or sometimes individuals, if personal tax credits are in play) that owe taxes in that state and want to reduce their bill. How do you find them? In some cases, the state authority helps match buyers and sellers (NJEDA often has a list of interested buyers, for instance). In other cases, companies use broker firms or tax credit marketplaces that specialize in these transactions. Large accounting or specialty tax firms sometimes broker credit deals, connecting a startup with unused credits to, say, a bank or insurance company that can use them. The buyer and seller negotiate a price – usually a percentage of the credit value. Market rates can vary, but most buyers expect a discount (they might pay 75–90% of the credit’s face value, depending on supply and demand and any state minimum). For example, if you have a $1 million credit, a buyer might offer $800k (80%). In NJ, you can’t go below 80% by law; in PA, it might be a bit higher due to competition among buyers.
- Execute sale with state documentation: Once a buyer is set and state approval is in hand, the sale is executed by signing a contract/transfer agreement and often notifying the state of the particulars (buyer name, credit amount, sale date, price). The state then issues a tax credit certificate or official document to the buyer for the purchased amount of credit. That certificate is golden – the buyer will attach it to their tax return to prove they have the right to claim the credit. Meanwhile, the seller delivers the credit certificate (or a copy) to the buyer and in return receives the cash payment (usually immediately or per contract terms). It’s essentially like selling any asset – there’s a contract and an exchange of property (the credit certificate) for money.
- Buyer claims the credit; seller uses funds: In the next tax filing, the buyer applies the purchased credit to their state tax liability, within the allowed limits. For instance, a PA buyer uses it that tax year up to 75% of what they owe, or an NJ buyer uses the full credit to cut their NJ Corporate Tax. The seller, now with cash in hand, can use the funds typically with some restrictions: e.g. NJ requires the money be spent on operational and R&D costs in-state. From an accounting perspective, the seller might record the cash minus any basis in the credit – often the credit had no cost basis, so it could be income (though sometimes states exempt it from income tax to not claw back what they just gave – it varies). In any case, the company now has additional capital to invest in growth without taking out loans or giving up equity.
- Reporting and compliance: Both parties usually have to report the transfer on their tax returns or via special forms. The seller might need to attach a state schedule showing the credit was transferred (and thus they’re not claiming it). The buyer attaches the certificate to claim it. States keep records to ensure the credit isn’t claimed twice or by the wrong party. It’s important both sides retain documentation (transfer agreement, state approval letter, etc.) in case of audit. If the credit is later challenged (say, the state finds some of the R&D expenses weren’t qualifying and reduces the credit), there are often indemnification clauses – the seller might have to refund the buyer for the portion of credit disallowed. Such scenarios are rare if everything was calculated correctly, but it underscores why careful documentation of qualified research expenses is crucial before you sell a credit. You don’t want to sell something that could be revoked, leaving your buyer empty-handed and upset.
Timeline: Selling an R&D credit is not instantaneous – it can take a few months. For instance, a company might apply for the credit in spring, get approval of credit in summer, apply for transfer in early fall, find a buyer by late fall, and complete the sale by year-end so the buyer can use it. Many states do these on an annual cycle. If you miss a deadline (like NJ’s June 30 application), you might have to wait till next year’s cycle. Planning ahead is key so you’re not stuck with credits you intended to sell but ran out of time to transact.
Transactional costs: There can be minor fees (NJ charges a small application fee, for example $2,500 for the NOL program). If a broker is involved, they might take a percentage of the sale (maybe a few percent). Despite these costs and the discount, selling credits often yields a much better immediate benefit than letting credits sit idle for years.
In short, selling a tax credit involves state oversight and approval, a willing buyer, and a formal transfer of the credit’s ownership. It’s a well-trodden path in states like NJ and PA – many local companies, accountants, and economic officials are familiar with the process, and entire mini-industries of consultants exist to facilitate it. Now, let’s delve into why companies choose to sell credits (the advantages) and also the potential downsides – which will help you decide if this route makes sense for your situation.
Why Sell Your R&D Credits?
If you have R&D credits burning a hole in your balance sheet, why would you sell them instead of just keeping them? There are several compelling reasons (and a few cautionary ones). Here we answer the what, why, and who of R&D credit sales:
Immediate cash vs. future tax relief. The primary reason to sell is immediate cash flow. A dollar of tax credit today is often more valuable to a young company than a dollar of tax savings years later. Many startups operate at a loss or breakeven as they invest in growth – they may not expect to owe significant taxes for 5, 10, or more years. Selling state credits turns that deferred benefit into today’s funding. It’s essentially a form of financing: you are monetizing a tax asset now to get money to hire engineers, buy equipment, or develop products, rather than waiting until you’re profitable enough to use the credit. The time value of money and the survival timeline of startups make upfront cash extremely valuable. As one might put it, “one dollar today to fund R&D may create far more value than a dollar saved on taxes five years from now.”
Non-dilutive capital. Unlike raising money from investors (equity financing) or taking loans, selling a tax credit yields non-dilutive funding. You’re not giving up any ownership or control in your company (as you would with venture capital), and you’re not incurring debt or interest obligations. It’s your own earned tax incentive being converted to money. Founders love this because it strengthens the company’s finances without strings attached or dilution of their equity. It’s essentially the government and a willing buyer financing your research because they want you to succeed in their state. Especially for tech startups who might otherwise have to give up a chunk of equity for a cash infusion, selling a credit is a very attractive alternative.
Remove uncertainty. Tax credits often come with uncertainty – you might hope to use them in future profitable years, but who knows when (or if) that will happen? Startups face the risk that they might never be able to utilize all their credits before they expire (some state credits expire after X years). By selling now, you lock in guaranteed value. Even though you sell at a discount (say 80% of face value), 80% in hand now might be better than 0% if your company never becomes taxable or if the credit expires unused. It also spares you the complexity of tracking carryforwards for years; you realize the value and move on. Additionally, tax laws can change – a generous credit program might be reduced or eliminated by future legislation (though usually existing credits are honored). Selling sooner can mitigate the risk of future changes that could devalue your credit.
Investor and board expectations. In some cases, your investors or board may prefer that you monetize credits to strengthen the balance sheet. For example, if you’ve got $5 million in state credits just sitting, converting them into $4 million cash via sale could extend your runway. It’s a way of extracting hidden value from your operations that might impress stakeholders. Also, some lenders view unused tax credits as intangible, uncertain assets, whereas cash is cash. So selling credits can improve your financial ratios or make it easier to secure loans since you’ve turned the credit into a tangible asset (cash) and possibly reduced your operating losses (if the credit sale is accounted as income or a reduction of expenses).
Why states allow it (the bigger picture). It’s worth noting why states facilitate these credit sales – because it aligns with policy goals. States want to attract and retain R&D-intensive companies (often startups that promise future jobs and innovation). If a state only offers a nonrefundable, non-transferable credit, a startup might see no short-term benefit and could choose to relocate to another state that provides grants or refundable credits. By allowing transfer or refund, the state is effectively saying: “We’ll help you get cash now for your R&D because we want you to keep innovating here.” It also broadens the impact of the credit – if a credit can only be used by the original company and they can’t use it, the state loses the intended impact. By allowing a transfer, the credit still gets used (by the buyer), ensuring someone benefits (either way the state loses the same tax revenue, but now the benefit is actually realized, not wasted). Plus, buyers (often large firms) appreciate it because they can indirectly subsidize local innovation while saving on taxes themselves. This dynamic can build an ecosystem where big companies support small ones (through buying credits), and small ones get funded to potentially become the next big employers in the state.
Who buys tax credits and why? The buyers are usually profitable corporations (or wealthy individuals if personal tax credits are transferable, though R&D credits are usually corporate). Common buyers include banks, insurance companies, manufacturers, and other firms with steady tax liabilities. Why do they buy? To reduce their state tax bill at a discount. If a company knows it will owe, say, $1 million in New Jersey taxes, it can pay $800k to purchase $1M of NJ credits from a startup – then use those credits to wipe out its tax. Net result: the buyer saved $200k (they spent $800k instead of paying $1M in tax). It’s essentially arbitrage allowed by the state – the buyer profits, the seller gets funding, and the state is indifferent between which taxpayer claims the credit. Some buyers also like the goodwill aspect: they’re helping local startups succeed (which in turn can lead to more business in the state, more future taxpayers, etc.). However, buyers will perform due diligence – they want to ensure the credit is valid and the seller followed all rules, since the buyer can’t use credits that aren’t legitimate. Big four accounting firms or tax advisors often vet credit transactions.
The strategic use case: Think of a biotechnology company in New Jersey with heavy R&D spend and no product revenue yet – they accumulate $2 million in NJ R&D credits over a couple years. Instead of letting that $2M carryforward while they’re cash-starved, they sell it through the NJEDA program for at least $1.6M cash. That $1.6M might fund another clinical trial or 6 more months of operations, increasing their chance of success. Meanwhile a big pharma company in NJ buys those credits and saves $400k on its taxes – effectively sponsoring the smaller company’s research in an indirect way. Both companies and the state’s biotech sector come out ahead.
All that said, selling credits is not a no-brainer in every situation. There are trade-offs and risks, which we will outline next. It’s important to weigh the pros and cons before deciding to sell your R&D credits.
Pros and Cons of Selling R&D Tax Credits
Selling your R&D credits can be a smart move, but it’s not without downsides. Let’s break out the key advantages and drawbacks side-by-side:
| Pros of Selling Credits | Cons of Selling Credits |
|---|---|
| Immediate cash infusion – You get funding now, which can be crucial for startups to continue R&D and operations. | Sold at a discount – You never get full 100% value; credits typically sell for ~80–90% of face value (you lose a portion of the benefit). |
| Non-dilutive financing – Raises money without giving up equity or taking on debt, preserving ownership and avoiding interest costs. | Limited to certain states – Only a few states allow sales. If your credits are from elsewhere, you can’t monetize them this way. |
| Reduces risk of expiration – Converts a maybe-useful-later asset into guaranteed money, avoiding the chance credits expire unused or laws change. | Eligibility hurdles – Strict requirements (e.g. tech industry only, employee count, profit status) mean not every company with credits can qualify to sell. |
| Boosts cash flow & runway – Strengthens the balance sheet, which may impress investors or lenders and enable more R&D investment or hiring. | Administrative effort – Requires paperwork, state approval, and often finding a buyer. It’s a process that takes time and professional guidance. |
| Mutually beneficial deals – Buyers save on taxes, sellers get cash, and states retain innovative companies – a win-win-win situation overall. | One-time use – Once sold, the credit is gone. You can’t get it back, and the buyer must use it that year or it’s wasted (no future carry for buyer). |
| No tax repayment obligation – Generally, you don’t have to pay back anything (unless fraud or leaving state) – it’s effectively free money from an unused asset. | Potential tax treatment – The cash received might be taxable income federally or reduce deductions (though states often exempt it). Accounting can be a bit complex for the sale transaction. |
| Encourages more R&D – Knowing you can monetize credits can encourage you to invest even more in research, since even losses yield cash. | Caps and fees – Programs have caps (e.g. annual state limits) and sometimes fees (application fees or broker commissions), which can limit how much you actually net. |
As shown above, selling credits can dramatically improve your company’s cash position and is a powerful financial tool, especially when you can’t currently benefit from the credits otherwise. However, the downsides mean you need to plan carefully: ensure you’re eligible, be prepared for the administrative process, and accept that you won’t get full face value. For many startups, the trade – say, $0.85 now vs $1 later – is well worth it to fuel growth or simply survive in the early years. For others, if they anticipate near-term profitability, it might make sense to hold onto credits and use 100% of their value to offset future taxes rather than sell at a discount.
Also consider opportunity cost: if you’re on the cusp of being profitable next year (able to use the credit internally), selling might not be wise. On the other hand, if you foresee several loss-making years, selling is likely beneficial. It’s essentially a financial decision about timing and certainty of benefit.
Avoiding Common Mistakes in Credit Sales
Like any financial transaction, selling R&D credits can go awry if not done correctly. Here are common mistakes and pitfalls to avoid:
1. Assuming you can sell when you can’t: A big mistake is not checking state rules carefully. Companies sometimes hear “tax credits can be sold” and assume theirs can – only to find out their state doesn’t allow it or they personally don’t qualify. Always confirm that the specific state credit program permits transfer or refund. For instance, you cannot sell federal credits, nor can you sell credits from states like California or New York. Even in transferable-credit states, confirm you meet the eligibility criteria before counting on a sale. An example pitfall: a company spends on R&D in Massachusetts expecting to sell the credit, but Massachusetts credits aren’t transferable (oops!). Or a company in PA with a large credit plans to sell it, but neglected to file the application by September 15 – no credit to sell because they missed the boat. Solution: Do your homework on the state’s program guidelines and timelines, or consult a tax advisor who knows your state’s incentive programs.
2. Neglecting tax compliance: States will not approve a credit transfer if you have outstanding tax issues. If your business owes back taxes, hasn’t filed all returns, or is not in good standing, that’s an immediate red flag. For example, Pennsylvania explicitly requires that the seller must have all state tax reports filed and no delinquency. New Jersey similarly checks that the company has filed its NJ tax returns by the program deadline. A common mistake is failing to file required forms like the state’s R&D credit calculation or forgetting to include Form 6765 with the application. Without formally claiming the credit first, you have nothing to sell. Solution: Ensure all your tax filings (income, withholding, sales tax, etc.) are current and any balances paid. File the necessary credit claim forms meticulously. Essentially, get your compliance house in order before initiating a sale – it will save a lot of headaches and prevent disqualification.
3. Misjudging the credit amount or validity: Some companies attempt to sell credits that the state later partially disallows because they weren’t calculated correctly. For instance, if some of your R&D expenses don’t qualify under audit, your credit might be reduced, and if you’ve sold that credit, it creates a messy situation. Another error is forgetting that IRC §280C adjustments (reducing deductions when taking the credit) or similar rules affect the net credit. Also, be careful not to try selling credits you haven’t officially been awarded yet. In PA’s program, you must first apply and be granted a credit allocation; you can’t sell an anticipated credit before the state confirms it. Solution: Calculate credits conservatively and consider a third-party study or accountant review to ensure your R&D expenses meet the criteria. Keep thorough documentation in case the buyer’s due diligence asks for it. Only proceed to sell once the credit is finalized/awarded by the state. This ensures you’re not selling something that might evaporate under scrutiny.
4. Timing and missing deadlines: Each program has its calendar. Missing an application deadline can mean waiting a full year. Missing a transfer deadline can kill a deal (buyers need time to use the credit by year-end). For example, New Jersey’s program closes applications by June 30 each fiscal year; if you miss it, you can’t sell until the next year’s cycle. If you’re counting on that money, a missed deadline can be dire. Similarly, if you leave finding a buyer until December, you might find buyers are tapped out or can’t complete paperwork in time to use the credit for that year. Solution: Plan ahead. Mark all relevant dates on your calendar. Start the process early – it’s better to have approval and a buyer lined up a few months before the tax year ends so everything can be finalized smoothly.
5. Not shopping around for buyers: Especially in states where a minimum price isn’t fixed, some sellers jump on the first offer, not realizing they might get a better deal. For example, a buyer might offer 75% of credit value, but perhaps credits in that state usually go for 85%. If you only talk to one potential buyer (say a friendly local company), you might undersell your credits. Conversely, working with a known broker or exchange might yield multiple bids. Solution: Even though time-consuming, try to contact multiple potential buyers or engage a broker who can access a network of buyers. Ensure the buyer is reputable and has the tax capacity to actually use the credit (so the deal doesn’t fall through). Compare offers, and remember, as the seller you want the highest price; as long as the buyer meets state criteria, it doesn’t matter to you who they are – so maximize your take.
6. Ignoring legal and tax advice: R&D credit transfer agreements are legal contracts. Mistakes here include not having an attorney review the sale contract or not understanding the tax implications of receiving the sale proceeds. For instance, will that cash be considered taxable income at the federal level? (Often, yes, it might be a form of other income or reduce deductible R&D expenses – which could slightly offset the benefit. It can depend on the state’s treatment too.) If you don’t plan for that, you might get a surprise tax bill on the sale proceeds. Solution: Involve your CFO, tax advisor, or lawyer early. They can help structure the sale agreement, ensure it complies with state law, and clarify how to report it. They’ll also include any needed protections (like what happens if the credit is later challenged – who indemnifies whom). The cost of professional advice is small compared to the value of the transaction and the risk if something goes wrong without guidance.
7. Compliance after the sale: Some programs impose post-sale requirements on the seller. For example, New Jersey requires the company to stay in NJ for 5 years after getting NOL/credit sale assistance and to use the funds for permitted expenses. A mistake would be selling the credits, then relocating the company to another state a year later – New Jersey could demand repayment of the funds as per the program rules. Solution: Be very aware of any commitments you agree to when selling credits. If you sell under a program that requires you to maintain certain employment levels or spend the money in-state, track those conditions. Breaking them could nullify the benefit or worse, incur penalties.
In summary, avoid being penny-wise and pound-foolish: don’t rush into a credit sale without proper planning and compliance. When done right, selling R&D credits is straightforward and beneficial. When done haphazardly, it can lead to disallowed credits, lost deals, or even legal trouble.
Pro tip: Treat the credit sale like any important funding round – do due diligence on your side and the buyer’s side. Engage experts if needed, and communicate transparently with the state authorities. This will greatly reduce the risk of any unpleasant surprises.
Key Terms and Concepts to Know
To navigate R&D credit sales confidently, here are some key terms and concepts (bolded) you should be familiar with, and what they mean in this context:
- R&D Tax Credit (Research Credit) – A dollar-for-dollar reduction in tax for qualified research expenditures. At federal level (under Section 41 of the Internal Revenue Code) and in many states. Non-transferable federally, but transferable/refundable in some states. Calculated on Form 6765 for federal and often mirrored at state level.
- Qualified Research Expenses (QREs) – The costs that qualify for the R&D credit (wages for researchers, supplies for experimentation, contract research costs, etc.). Only these expenses generate credits. Properly identifying QREs is crucial; selling a credit implicitly warrants that these were valid expenses meeting the IRS four-part test (permitted purpose, elimination of uncertainty, process of experimentation, technological in nature).
- Carryforward / Carryback – If you can’t use a credit, you might carry it forward to offset future tax years (e.g., up to 15 or 20 years) or carry it back to prior years (some states allow a 1-year carryback; e.g., North Dakota allows 3-year carryback of R&D credits). When you sell a credit, you typically give up any carryforward – the buyer uses it immediately (no further carryforwards allowed for them in most cases).
- Transferable Credit – A tax credit that state law permits to be sold or assigned to another taxpayer. It becomes a sort of commodity. Not all credits are transferable; states often specify which credits (R&D, film, historic rehab, etc.) can be transferred. We discussed states with transferable R&D credits (NJ, PA, etc.).
- Refundable Credit – A credit that, if you can’t use it against taxes, is paid out in cash to you by the government. Essentially a guaranteed benefit. Connecticut’s 65% refund for small companies and Arizona’s 75% refund are examples in the R&D realm. Refundable means you don’t need a buyer – the state “buys” the credit. Non-refundable means it only offsets tax or must be carried forward (unless transferred).
- Credit Certificate – An official document issued by a state confirming that a taxpayer (could be the seller initially, then reissued to buyer) is entitled to a certain amount of tax credit. This is the instrument used in transfers; the buyer receives a new certificate in their name for the credit amount purchased. It’s like the title to property – needed to claim the credit.
- Net Operating Loss (NOL) Program – In NJ’s context (and some other states), NOLs (tax losses) can be sold alongside R&D credits. NOL is a tax term for when deductible expenses exceed income, creating a loss that can often be carried forward to offset future profits. NJ’s program often lumps NOLs and R&D credits together for sale (both are tax attributes you can sell). Key point: selling NOLs is unique to NJ’s program; most other discussions here are purely about credits, not losses.
- **Qualified Small Business (QSB) – In federal terms, this is a company (with < $5 million gross receipts and <=5 years of existence) that can elect the payroll tax offset for the R&D credit. In some state contexts, “small business” may define eligibility for enhanced credits or transfer/refund (e.g., Pennsylvania’s < $5M assets for small business credit set-aside; Arizona’s <150 employees for refund). Knowing if you’re a “QSB” can open certain benefits like that federal payroll credit or special state provisions.
- Buyer (Transferee) / Seller (Transferor) – The parties in a credit sale. The seller/transferor is the original company that earned the credit and is selling it. The buyer/transferee is the company purchasing the credit to use on their tax return. Documentation will refer to these terms. The buyer typically must be subject to the same tax (e.g., a PA corporate taxpayer can buy PA credits). The relationship is usually arms-length; sometimes, however, a related party sale might be restricted (states often want the sale to be to an unrelated party to avoid abuse, which is the case in NJ’s program).
- One-time Transfer – Most states stipulate a credit can only be sold once. The buyer cannot resell it. For example, PA and NJ explicitly ban second-generation transfers. This prevents an endless secondary market and trading; it’s a controlled one-time move. Keep this in mind: as a seller, you want to pick a buyer who will definitely use it, because they can’t pass it on if they fail to utilize it.
- Section 280C – A federal tax rule requiring taxpayers to reduce the deductible expenses by the amount of the credit (or take a reduced credit) to prevent a double benefit. While this mainly affects how you claim the credit on your own taxes, if you sell the credit, you may need to consider how that interplay worked when you originally computed it. It’s technical, but essentially, make sure your credit calculation is correct net of any required adjustments.
- Economic Development Authority – Generic term for state agencies like NJEDA, Arizona Commerce Authority, etc., which administer these programs. They are key contacts for applications and information. Each such agency often publishes program guidelines and may even list successful transactions or stats annually.
Understanding these terms will help you navigate discussions and documentation related to selling R&D credits. You’ll sound like an expert talking about transferable credits, QREs, and certificates – and more importantly, you’ll fully grasp the moving pieces in these transactions.
Examples and Case Studies
Sometimes the best way to understand a concept is through concrete examples. Let’s look at a couple of scenarios demonstrating R&D credit sales in action, as well as some real-world outcomes:
Example 1: Biotech Startup in New Jersey (“BioCo”) – BioCo is a 4-year-old biotechnology company based in New Jersey. They’ve been in R&D mode, not yet profitable (net losses each year). Over the last few years, BioCo accumulated an NJ R&D tax credit of $500,000 and also has substantial NJ net operating losses. BioCo is running low on cash but needs to continue expensive lab research and clinical trials. They decide to use New Jersey’s NOL Transfer Program. They apply by the deadline and get approved to sell the full $500k credit (and some of their NOL). NJEDA matches them with PharmaInc, a large pharmaceutical company in NJ that owes state taxes and is happy to purchase BioCo’s credits. The program requires at least 80% sale value; due to competitive demand, PharmaInc agrees to pay 85% of the credit’s value. So BioCo sells the $500k credit for $425,000 in cash. They also sell some NOL, bringing total cash to, say, $1 million. This non-dilutive $1M infusion extends BioCo’s runway by a year, allowing them to reach the next milestone (perhaps attracting a venture capital round at better terms). PharmaInc, in turn, uses the $500k credit to cut its state taxes (it basically saved ~$75k compared to paying tax in full, since it paid $425k for a $500k reduction). Two years later, BioCo launched a successful product, started earning income, and now pays taxes – precisely the outcome NJ hoped for by helping them earlier. BioCo continues to base its operations in NJ (a condition of the help they got). This example underscores how selling credits provided critical funding at a make-or-break time for a startup.
Example 2: Small Tech Firm in Pennsylvania (“TechSolutions LLC”) – TechSolutions is a software development LLC in Pennsylvania with 10 employees. It qualifies as a small business under PA’s program. In 2024, it spends a lot on developing a new cloud platform and earns a PA R&D credit of $100,000. However, as a passthrough entity, TechSolutions’ income flows to the owners – and they actually have a loss for 2024 (so the credit can’t be used on their PA personal tax either, since no tax is due). They decide to sell the $100k credit. They file their state R&D credit application by September 15, and in December PA awards them the $100k credit certificate. Now, TechSolutions connects with a manufacturing company in PA that expects a high tax bill. That company agrees to buy the $100k credit for $90,000 (90% is a relatively good price, reflecting strong demand for credits). PA’s DCED approves the assignment in early 2025. TechSolutions transfers the credit – the manufacturing company (buyer) gets the certificate for $100k credit, which it will use to offset its 2024 PA taxes by that full amount (note: it owes, say, $200k in taxes, so it can use the $100k credit to cover half – within the 75% allowance since $100k is 50% of $200k, which is fine). TechSolutions receives $90k cash. For TechSolutions’ owners, this $90k is a much-needed cash injection – it helps cover operating expenses and avoid taking out a loan. They effectively monetized their innovation incentive. Come tax time, the buyer uses the credit, reducing its tax payment by $100k (it essentially saved $10k net). TechSolutions will report the sale on its books; for tax, if structured properly, it may treat the $90k as an addition to income (since the expenses that created the credit were likely deducted already). Regardless, the key point is, both parties benefited through the state’s assignment program, and PA achieved its goal of encouraging the small company’s R&D and also giving a break to a larger employer.
Real-world evidence of impact: New Jersey’s program reports are a great evidence source. For instance, in 2023, 34 NJ companies (mostly tech and life science startups) sold credits/NOLs for a total of $68 million in cash raised. That’s an average of $2 million per company – not trivial at all. Some individual companies have publicly praised the program: e.g., a NJ biotech CEO noted they’ve raised over $19 million across several years by selling NJ credits, calling it critical non-dilutive funding that helped them push forward with life-saving research. Similarly, in Pennsylvania, hundreds of companies have used credit assignments since the early 2000s – the state publishes annual reports of credit usage. By allowing sales, PA ensures that each year close to 100% of the $55M cap actually gets utilized (if not by original earners then by buyers), whereas without transferability, a chunk might go unclaimed due to companies with losses.
Another case: North Dakota – It’s been reported that a few local startups in the energy technology space leveraged the credit transfer provision to sell around $50k of credits each to bigger oil companies in ND, giving them a little extra cash to prototype new tools. Though small scale, that’s money that might have otherwise been locked away until those startups had revenue (which could be never if they failed due to lack of funds).
Comparative outcome: It’s informative to compare a company in a transferable-credit state vs. one in a non-transferable state. Imagine two similar startups: one in New Jersey, one in California. Each has $1 million in R&D expenses and thus ~ $100k in state R&D credits (assuming state credit roughly 10% of expenses in both states). The NJ startup can sell its $100k credit for ~$80k cash and use that to hire another engineer. The California startup, however, cannot sell its credit – it can only carry it forward. If it doesn’t become profitable for, say, 5 years, that $100k credit just sits unused (no immediate benefit). The NJ company might have a competitive edge thanks to the extra funding. This simplified scenario illustrates why many see transferable credits as a boost to business growth.
In essence, the examples and evidence show that selling R&D credits has real, tangible benefits for companies and that states permitting such sales have seen positive outcomes (startups surviving and expanding, tax credit resources fully utilized, etc.). However, as we’ve cautioned, ensure you follow the rules and best practices – the companies in these success stories did their due diligence and worked within the program frameworks.
Now, to wrap up, let’s address some frequently asked questions about selling R&D credits – these quick Q&As distill a lot of what we’ve covered into bite-sized answers.
FAQ: Selling R&D Tax Credits (Your Questions Answered)
Q: Can a business sell its R&D tax credits at the federal level?
A: No. The federal R&D credit isn’t transferable. Startups can use it against payroll taxes (up to $500k/year), but you cannot sell or transfer federal credits to other companies. (No exceptions aside from the payroll offset.)
Q: Do all states allow you to sell R&D credits?
A: No. Only a handful of states permit selling or transferring R&D tax credits (e.g. NJ, PA, AZ, ND). Many states offer R&D credits that are non-transferable (you can only carry them forward or sometimes get refunds in special cases).
Q: Is it legal to sell state tax credits?
A: Yes – if the state law explicitly allows it. In states with authorized programs, selling tax credits is a legal, state-sanctioned process. It’s facilitated by state agencies and requires their approval. (It’s not a loophole; it’s an intended feature in those jurisdictions.)
Q: Will I get the full value of my R&D credit when I sell it?
A: No. Credits are sold at a discount. Typically, sellers get around 80–90% of the credit’s face value in cash. You sacrifice a portion of the credit’s value to the buyer in exchange for immediate cash. (The exact percentage depends on the market and any state minimum pricing.)
Q: Who buys R&D tax credits?
A: Yes, there’s a market of buyers. Usually profitable companies with tax liabilities in the state buy credits. Common buyers are large corporations like banks, insurers, or manufacturers looking to save on state taxes. (They purchase credits at a discount to reduce their own tax bills.)
Q: Can the same credit be sold more than once?
A: No. Once an R&D credit is sold/assigned, the buyer must use it – resale is not allowed. State rules mandate a one-time transfer. (The credit can’t be flipped repeatedly; it’s a single transaction from the original owner to the end-user.)
Q: Do I owe tax on the money received from selling a credit?
A: Yes, possibly. The cash you get might be considered taxable income at the federal level or reduce your deductible R&D expenses. States often exclude it from state income, but for IRS purposes, consult a tax advisor. (Plan for a potential federal tax impact on the sale proceeds.)
Q: What happens if my startup leaves the state after selling its credits?
A: Leaving too soon can be a problem. Some programs (like NJ’s) require you to stay in-state for X years after the sale and use the funds for local operations. If you violate those terms, you may have to repay the credit money. (Always check post-sale obligations.)
Q: Are there fees or costs to sell R&D credits?
A: Yes, minor ones. Some states charge an application fee (e.g., NJ’s $2,500) and if you use a broker, they may take a commission. But there’s no huge cost – the main “cost” is the discount on the credit’s value. (Factor in small fees when calculating your net benefit.)
Q: Can individuals sell R&D credits, or only companies?
A: In practice, it’s typically companies. R&D credits are usually a business incentive. An individual could only have an R&D credit if they were a sole proprietor or partner in a business, and even then, transfer programs are geared toward corporate entities. (So, effectively, it’s businesses selling to other businesses in the allowed states.)
Q: Does selling a credit affect my ability to claim other tax benefits?
A: No, it shouldn’t. Selling a state R&D credit doesn’t impact your federal R&D credit claim or other deductions, except you can’t use the state credit yourself once sold. Ensure you claimed the credit properly first. (It’s isolated to that credit – just follow the state’s procedures and you’re fine.)